Back to top
more

Retrophin, Inc. (RTRX)

(Delayed Data from NSDQ)

$19.72 USD

19.72
376,763

+0.61 (3.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $19.75 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Corcept (CORT) Strives to Commercialize Key Drug Korlym

by Zacks Equity Research

We issued an updated report on Corcept Therapeutics Incorporated (CORT) on Mar 28.

    Vertex Combo Data on Kalydeco+VX-661 Positive in Phase III

    by Zacks Equity Research

    Vertex Pharmaceuticals (VRTX) announced positive data from two phase III studies evaluating its lead marketed drug Kalydeco (ivacaftor) in combination with tezacaftor VX-661 (tezacaftor) in patients suffering from cystic fibrosis.

      Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

      by Zacks Equity Research

      Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).

        Will Endo's Troubles Continue to Dent Performance in 2017?

        by Zacks Equity Research

        2017 will continue to challenging for Endo Pharmaceuticals (ENDP) as the generics base business and the legacy branded pain franchise are expected to decline further.

          Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion

          by Zacks Equity Research

          Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.

            Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion

            by Zacks Equity Research

            Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.

              Merrimack (MACK) Starts Enrollment in Solid Tumors Study

              by Zacks Equity Research

              Merrimack Pharmaceuticals, Inc. (MACK) announced that it has enrolled the first patient in a phase I study on MM-310 for solid tumors.

                Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA

                by Zacks Equity Research

                Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

                  Shire (SHPG) Rare Disease Drug Gets Fast Track Designation

                  by Zacks Equity Research

                  Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).

                    Alexion (ALXN) Files for Soliris' Label Expansion in Japan

                    by Zacks Equity Research

                    Alexion Pharmaceuticals, Inc. (ALXN) announced that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) for the label expansion for Soliris to treat patients with refractory generalized myasthenia gravis (gMG).

                      Keryx's Auryxia Added to Largest Medicare Part D Plan

                      by Zacks Equity Research

                      Keryx Biopharmaceuticals, Inc. (KERX) announced that the nation's largest Medicare Part D plan sponsor has added Auryxia (ferric citrate) to its Medicare Part D plan formularies.

                        Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA

                        by Zacks Equity Research

                        Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Bausch + Lomb announced that the FDA has set a PDUFA date on Aug 24 for its decision on the New Drug Application (NDA) for latanoprostene bunod ophthalmic solution, 0.024%.

                          Mylan Receives Tentative Approval from FDA for HIV Therapy

                          by Zacks Equity Research

                          Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and Viread, 400 mg/300 mg/300 mg (TLE400).

                            Bristol-Myers Squibb and CytomX Therapeutics Extend Deal

                            by Zacks Equity Research

                            Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.

                              Alnylam's LDL-Lowering Drug Positive in Phase II Study

                              by Zacks Equity Research

                              Alnylam Pharmaceuticals, Inc. (ALNY) and its partner The Medicines Company (MDCO) announced positive final results from the phase II study, ORION-1, on their experimental PCSK9 inhibitor, inclisiran.

                                Alexion (ALXN) Licenses Artubus Technology for Rare Diseases

                                by Zacks Equity Research

                                Alexion Pharmaceuticals, Inc. (ALXN) has recently licensed Arbutus Biopharma proprietary LNP technology for use in rare disease programs.

                                  Valeant (VRX) Shares up on ValueAct's 5.2% Stake Increase

                                  by Zacks Equity Research

                                  Shares of Valeant Pharmaceuticals (VRX) were up after investor ValueAct Capital management increased its stake in the company to 5.2%.

                                    Shire's (SHPG) Cinryze Label Expanded for Pediatric Use

                                    by Zacks Equity Research

                                    Shire plc (SHPG) announced that the European Commission (EC) has approved a label extension for drug Cinryze for use in pediatrics.

                                      Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA

                                      by Zacks Equity Research

                                      Endo International plc (ENDP) announced that the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees had consented that the benefits of reformulated Opana ER no longer outweigh its risks.

                                        Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4

                                        by Zacks Equity Research

                                        Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 5 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate and also narrower than the loss of 7 cents in the year-ago quarter.

                                          Allergan (AGN) and Editas Tie Up to Treat Eye Diseases

                                          by Zacks Equity Research

                                          Allergan plc's (AGN), and Editas Medicine, Inc. (EDIT), entered into a strategic research and development agreement.

                                            Infinity (INFI) Reports Narrower-than-Expected Loss in Q4

                                            by Zacks Equity Research

                                            Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 46 cents per share in fourth-quarter 2016, much narrower than the Zacks Consensus Estimate loss of 63 cents.

                                              Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4

                                              by Zacks Equity Research

                                              Endocyte, Inc. (ECYT) reported a fourth-quarter 2016 loss of 26 cents per share, wider than both the Zacks Consensus Estimate of a loss of 25 cents and the year-ago loss of 23 cents.